Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Double-Blind Placebo-Controlled Phase 2 Study of Acazicolcept (ALPN-101) in Systemic Lupus Erythematosus
2020-004047-86Phase 2Completed
- Sponsor
- Alpine Immune Sciences, Inc.
- Start
- Jun 2021
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Acazicolcept with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Jun 2021; status: completed.
02
Drugs
acazicolcept
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2020-004047-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004047-86.